Publications
88
Citations
1,678
Est. group size
~17
Recurring co-author estimate
Active years
22
Publishing since 2005
Dr. Reinbolt's research focuses on breast cancer treatment, particularly understanding and predicting side effects from chemotherapy such as peripheral neuropathy (nerve damage causing numbness/pain) and other treatment-related toxicities. Her work also examines how patients and clinicians report these side effects differently, and how biological markers of aging may help predict who is at risk for treatment complications. She has additionally contributed to studies on improving cancer diagnostic and care delivery systems, including responses to pandemic-related healthcare access challenges.
Publication output rose from 2017 to a peak around 2020-2022, then declined sharply with little to no output in 2023-2025, suggesting a slowing pace in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer
UNC Libraries · 2025
- A New Front Door: The James Cancer Diagnostic Center
Oncology Issues · 2023
- A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer
npj Breast Cancer · 2022
- A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer
medRxiv · 2022
- BPI22-023: Strategies to Prevent Unplanned Emergency Department (ED) Utilization in the COVID-19 Era
Journal of the National Comprehensive Cancer Network · 2022
- QIM22-202: Cancer Diagnostic Center: A Response to the COVID-19 Pandemic to Improve Access to Diagnostic Testing
Journal of the National Comprehensive Cancer Network · 2022
- Readmission risk identification: Implementation of a patient-centered interview.
Journal of Clinical Oncology · 2022
- Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer
Breast Cancer Research and Treatment · 2021
- Congruence of patient‐ and clinician‐reported toxicity in women receiving chemotherapy for early breast cancer
Cancer · 2020
- Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, <i>p16INK4a</i>
JNCI Cancer Spectrum · 2020
- Patient‐reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer
Cancer · 2020
- Patient‐reported and clinician‐reported chemotherapy‐induced peripheral neuropathy in patients with early breast cancer: Current clinical practice
Cancer · 2019
- Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer
The Oncologist · 2018
- Patient(Pt)-reported toxicities during breast cancer (BC) chemotherapy (CRx): Associations with pre-treatment (Tx) measures of quality of life (QOL) and Tx discontinuation.
Journal of Clinical Oncology · 2018
- Patient(Pt)-reported toxicities by chemotherapy regimen for early breast cancer (BC) (LCCC1334/1440).
Journal of Clinical Oncology · 2018
- Journal of Clinical Oncology×11
- Cancer Research×6
- Cancer×3
- Cancer Medicine×3
- Supportive Care in Cancer×2
- Maryam B. Lustberg
Medicine · The Ohio State University
- Ewa Mrózek
Medicine · The Ohio State University
- Guanglong Jiang
Medicine · Indiana University
- Kathy D. Miller
Medicine · Indiana University
- Erica Cantor
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile